PL2282778T3 - Nowe podejścia terapeutyczne do leczenia choroby alzheimera i powiązanych zaburzeń poprzez modulację angiogenezy - Google Patents
Nowe podejścia terapeutyczne do leczenia choroby alzheimera i powiązanych zaburzeń poprzez modulację angiogenezyInfo
- Publication number
- PL2282778T3 PL2282778T3 PL09738185T PL09738185T PL2282778T3 PL 2282778 T3 PL2282778 T3 PL 2282778T3 PL 09738185 T PL09738185 T PL 09738185T PL 09738185 T PL09738185 T PL 09738185T PL 2282778 T3 PL2282778 T3 PL 2282778T3
- Authority
- PL
- Poland
- Prior art keywords
- angiogenesis
- modulation
- related disorders
- alzheimer disease
- new therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4858308P | 2008-04-29 | 2008-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2282778T3 true PL2282778T3 (pl) | 2017-08-31 |
Family
ID=41222690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09738185T PL2282778T3 (pl) | 2008-04-29 | 2009-04-29 | Nowe podejścia terapeutyczne do leczenia choroby alzheimera i powiązanych zaburzeń poprzez modulację angiogenezy |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11291670B2 (pl) |
| EP (1) | EP2282778B1 (pl) |
| JP (1) | JP5721230B2 (pl) |
| KR (1) | KR101660401B1 (pl) |
| CN (1) | CN102065898B (pl) |
| AU (1) | AU2009242126B2 (pl) |
| BR (1) | BRPI0911520A2 (pl) |
| CA (1) | CA2722453C (pl) |
| CY (1) | CY1118956T1 (pl) |
| DK (1) | DK2282778T3 (pl) |
| EA (1) | EA021731B1 (pl) |
| ES (1) | ES2622504T3 (pl) |
| HR (1) | HRP20170531T1 (pl) |
| HU (1) | HUE033726T2 (pl) |
| IL (1) | IL208982B (pl) |
| LT (1) | LT2282778T (pl) |
| MX (1) | MX2010011881A (pl) |
| NZ (1) | NZ589307A (pl) |
| PL (1) | PL2282778T3 (pl) |
| PT (1) | PT2282778T (pl) |
| SI (1) | SI2282778T1 (pl) |
| WO (1) | WO2009133141A2 (pl) |
| ZA (1) | ZA201008037B (pl) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CN104127434B (zh) * | 2008-04-29 | 2017-10-13 | 法奈科斯公司 | 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物 |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| NZ613291A (en) | 2008-11-19 | 2014-11-28 | Forum Pharmaceuticals Inc | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| SG185594A1 (en) | 2010-05-17 | 2012-12-28 | Envivo Pharmaceuticals Inc | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| JP5820476B2 (ja) | 2010-08-24 | 2015-11-24 | アルギアックス ファルマコウティカルス ゲーエムベーハーＡＬＧＩＡＸ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＧｍｂＨ | レフルノミドおよびマロノニトリラマイドの新規の使用 |
| DE102010062810B4 (de) * | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
| DK2673363T3 (da) * | 2011-02-11 | 2017-11-13 | Univ Rockefeller | Behandling af angiogenesesygdomme |
| US9867837B2 (en) | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| DK2727588T3 (en) | 2011-03-01 | 2018-12-10 | Pharnext | Baclofen- and acamprosate-based therapy for neurological disorders |
| UA115968C2 (uk) * | 2011-03-01 | 2018-01-25 | Фарнекст | Нові композиції для лікування неврологічних захворювань |
| JP6430445B2 (ja) * | 2011-03-01 | 2018-11-28 | ファーネクストＰｈａｒｎｅｘｔ | バクロフェンおよびアカンプロセートに基づく神経疾患の治療 |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
| HUE034212T2 (en) * | 2012-03-01 | 2018-02-28 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| AU2013224959B2 (en) * | 2012-03-01 | 2017-12-07 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| RU2017136693A (ru) | 2012-05-08 | 2019-02-08 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
| US8962020B2 (en) * | 2012-07-26 | 2015-02-24 | Glycadia Inc. | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
| EP2705841A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR101579008B1 (ko) * | 2013-09-25 | 2015-12-22 | 경북대학교 산학협력단 | ERR-γ 저해제를 포함하는, 망막병증의 예방 또는 치료용 약학적 조성물 및 이의 용도 |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| EP3104850A1 (en) | 2014-02-11 | 2016-12-21 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| CN110643705A (zh) * | 2014-03-19 | 2020-01-03 | 上海吉凯基因化学技术有限公司 | 人dgkz基因的用途及其相关药物 |
| US20180028520A1 (en) * | 2014-09-30 | 2018-02-01 | The Trustees Of Columbia University In The City Of New York | Methods and pharmaceutical compositions for treatment of amyotrophic lateral sclerosis |
| WO2016201086A1 (en) * | 2015-06-12 | 2016-12-15 | Rush University Medical Center | Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein |
| AU2017216288B2 (en) * | 2016-02-05 | 2022-06-02 | Pharnext | Novel combinatorial therapies of neurological disorders |
| US11033524B2 (en) | 2016-11-23 | 2021-06-15 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating disorders associated with cortico-hippocampal hyperactivity |
| EP3615017A1 (en) | 2017-04-24 | 2020-03-04 | Pharnext | Idalopirdine-based combinatorial therapies of alzheimer's disease |
| US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
| WO2019094434A1 (en) * | 2017-11-07 | 2019-05-16 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
| CN111084768A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| JPWO2020111171A1 (ja) * | 2018-11-29 | 2021-11-25 | 雪印メグミルク株式会社 | 血管新生促進用組成物 |
| CN110806488B (zh) * | 2019-12-06 | 2020-09-25 | 南京医科大学 | Drd5及其激动剂在制备治疗炎症性疾病的药物中的应用 |
| AU2021249050A1 (en) * | 2020-03-31 | 2022-11-17 | Wilfred Jefferies | Methods for treating alzheimer's disease |
| WO2023059867A1 (en) * | 2021-10-08 | 2023-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds for treating or preventing alzheimer's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH072688A (ja) * | 1991-06-11 | 1995-01-06 | Rikomu:Kk | 腸内有毒腐敗産物抑制剤 |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| ATE174218T1 (de) * | 1993-01-08 | 1998-12-15 | Hoechst Ag | Verwendung von leflunomid zur hemmung von interleukin 1 beta |
| AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
-
2009
- 2009-04-29 ES ES09738185.9T patent/ES2622504T3/es active Active
- 2009-04-29 CA CA2722453A patent/CA2722453C/en active Active
- 2009-04-29 MX MX2010011881A patent/MX2010011881A/es active IP Right Grant
- 2009-04-29 KR KR1020107026061A patent/KR101660401B1/ko not_active Expired - Fee Related
- 2009-04-29 JP JP2011506707A patent/JP5721230B2/ja not_active Expired - Fee Related
- 2009-04-29 AU AU2009242126A patent/AU2009242126B2/en not_active Ceased
- 2009-04-29 BR BRPI0911520A patent/BRPI0911520A2/pt not_active Application Discontinuation
- 2009-04-29 LT LTEP09738185.9T patent/LT2282778T/lt unknown
- 2009-04-29 WO PCT/EP2009/055205 patent/WO2009133141A2/en active Application Filing
- 2009-04-29 DK DK09738185.9T patent/DK2282778T3/en active
- 2009-04-29 PL PL09738185T patent/PL2282778T3/pl unknown
- 2009-04-29 EP EP09738185.9A patent/EP2282778B1/en active Active
- 2009-04-29 NZ NZ589307A patent/NZ589307A/en not_active IP Right Cessation
- 2009-04-29 PT PT97381859T patent/PT2282778T/pt unknown
- 2009-04-29 SI SI200931641A patent/SI2282778T1/sl unknown
- 2009-04-29 HU HUE09738185A patent/HUE033726T2/en unknown
- 2009-04-29 CN CN200980122773.4A patent/CN102065898B/zh active Active
- 2009-04-29 EA EA201071244A patent/EA021731B1/ru not_active IP Right Cessation
-
2010
- 2010-10-28 IL IL208982A patent/IL208982B/en active IP Right Grant
- 2010-10-29 US US12/915,709 patent/US11291670B2/en active Active
- 2010-11-10 ZA ZA2010/08037A patent/ZA201008037B/en unknown
-
2017
- 2017-04-03 HR HRP20170531TT patent/HRP20170531T1/hr unknown
- 2017-04-13 CY CY20171100439T patent/CY1118956T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE033726T2 (en) | 2017-12-28 |
| CA2722453A1 (en) | 2009-11-05 |
| LT2282778T (lt) | 2017-06-26 |
| CN102065898A (zh) | 2011-05-18 |
| PT2282778T (pt) | 2017-04-27 |
| ES2622504T3 (es) | 2017-07-06 |
| EA021731B1 (ru) | 2015-08-31 |
| US20120058992A1 (en) | 2012-03-08 |
| JP2011518864A (ja) | 2011-06-30 |
| WO2009133141A3 (en) | 2009-12-30 |
| EP2282778B1 (en) | 2017-03-08 |
| BRPI0911520A2 (pt) | 2017-06-13 |
| JP5721230B2 (ja) | 2015-05-20 |
| CY1118956T1 (el) | 2018-01-10 |
| CN102065898B (zh) | 2015-08-26 |
| NZ589307A (en) | 2012-04-27 |
| ZA201008037B (en) | 2011-08-31 |
| DK2282778T3 (en) | 2017-05-01 |
| HRP20170531T1 (hr) | 2017-06-16 |
| AU2009242126B2 (en) | 2014-03-27 |
| EA201071244A1 (ru) | 2011-06-30 |
| WO2009133141A2 (en) | 2009-11-05 |
| IL208982A0 (en) | 2011-01-31 |
| AU2009242126A1 (en) | 2009-11-05 |
| IL208982B (en) | 2018-03-29 |
| KR101660401B1 (ko) | 2016-09-27 |
| SI2282778T1 (sl) | 2017-07-31 |
| CA2722453C (en) | 2018-03-20 |
| US11291670B2 (en) | 2022-04-05 |
| KR20110010734A (ko) | 2011-02-07 |
| MX2010011881A (es) | 2011-07-01 |
| EP2282778A2 (en) | 2011-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201008037B (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis | |
| ZA201008039B (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | |
| IL219412A0 (en) | New therapeutic approaches for treating alzheimer disease | |
| HRP20182147T8 (hr) | Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja | |
| HK1158172A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
| ZA200905962B (en) | Combination therapy for treatment of immune disorders | |
| GB0703909D0 (en) | Treatment of anxiety disorders | |
| GB0915259D0 (en) | Sulphur-linked compounds for treating ophthalmic diseases and disorders | |
| ZA201202346B (en) | Therapeutic agent for mood disorders | |
| HRP20171418T1 (hr) | Terapeutsko sredstvo za poremećaje anksioznosti | |
| IL210558A0 (en) | Treatment of anxiety disorders | |
| SI2278962T1 (sl) | Postopki za zdravljenje dermatoloških motenj | |
| ZA201100325B (en) | Treatment of anxiety disorders |